Trials / Completed
CompletedNCT00550329
Bioequivalence Study Of Glucotrol XL 2.5 Mg Tablets
An Open-Label, Randomized, Single-Dose, Two-Way Crossover Bioequivalence Study Of Glucotrol XL 2.5 Mg Tablets Manufactured At Brooklyn, New York Versus At Barceloneta, Puerto Rico In Healthy Subjects
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 32 (planned)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The objective of this study is to determine the bioequivalence of Glipizide GITS (Glucotrol XL) 2.5 mg tablets manufactured at the Brooklyn, New York facility versus tablets manufactured at the facility in Barceloneta, Puerto Rico.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Glipizide GITS |
Timeline
- Start date
- 2007-10-01
- Completion
- 2007-11-01
- First posted
- 2007-10-29
- Last updated
- 2008-10-21
Locations
1 site across 1 country: Singapore
Source: ClinicalTrials.gov record NCT00550329. Inclusion in this directory is not an endorsement.